Anupam_Rasayan acquires Bliss_GVS_Pharma
Analysis based on 13 articles · First reported May 23, 2026 · Last updated May 23, 2026
The acquisition of Bliss GVS Pharma by Anupam Rasayan India is expected to positively impact both companies' stock prices due to anticipated synergies and expanded market reach. Anupam Rasayan India's stock may see an increase as it diversifies its portfolio and strengthens its position in the pharmaceutical value chain, while Bliss GVS Pharma's shareholders benefit from the acquisition price.
Anupam Rasayan India India Ltd. has announced its definitive agreement to acquire up to a 74.2% equity stake in Bliss GVS Pharma Limited. This strategic acquisition involves an initial share purchase of 43.3-48.2% at ₹299 per share, followed by an open offer to public shareholders for an additional 26% stake at the same price. The total purchase consideration, exceeding ₹1,360 crore, is being financed through a combination of a ₹300 crore term loan and non-controlling equity instruments. This move aligns with Anupam Rasayan India's vision to build an integrated global life sciences and specialty pharmaceutical platform, leveraging Bliss GVS Pharma's expertise in pharmaceutical formulations, particularly suppositories and pessaries, and its strong international presence in Africa, Asia, and Americas. The acquisition is expected to unlock significant synergies, expand product offerings, strengthen regulated market presence, and accelerate innovation across global markets, including Europe and the Americas.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard